<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852084</url>
  </required_header>
  <id_info>
    <org_study_id>761</org_study_id>
    <nct_id>NCT01852084</nct_id>
  </id_info>
  <brief_title>Hydrophobic Acrylic Toric IOL Designed to Reduce the Effects of Preoperative Corneal Astigmatism</brief_title>
  <official_title>To Evaluate the Safety and Effectiveness of the EnVista速 One-Piece Hydrophobic Acrylic Toric IOL Designed to Reduce the Effects of Preoperative Corneal Astigmatism on Postoperative Refraction Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigational enVista IOL, Model MX60Tis equipped with toric optics and axis marks on&#xD;
      the posterior surface to minimize the possibility of surgically induced astigmatism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigational enVista Toric IOL, Model MX60T, and the currently approved Model MX60,&#xD;
      are identical with the exception of the addition of toric optics and axis marks on the&#xD;
      posterior optic surface for the correction of astigmatism on the Model MX60T. Both lenses&#xD;
      have an aspheric biconvex optic with a modified C haptic monoblock, single-piece design. The&#xD;
      design and material of both the MX60 and MX60T allow them to be folded and inserted through&#xD;
      small incisions to minimize the possibility of surgically induced astigmatism (SIA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 6, 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">July 18, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Dioptric Change in Cylinder</measure>
    <time_frame>Baseline, Final Visit (scheduled within window: days 120-180)</time_frame>
    <description>Dioptric change in cylinder from the preoperative keratometric cylinder magnitude to postoperative manifest refraction cylinder magnitude (referenced to the corneal plane).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Intraocular Lens (IOL) Rotation of Less Than or Equal to Five Degrees</measure>
    <time_frame>Form 3 Visit (window: days 30-60), Final Visit (window: days 120-180)</time_frame>
    <description>Intraocular Lens (IOL) rotation of less than or equal to five degrees between Forms 3 (scheduled within window: days 30-60) and final visit (scheduled within window: days 120-180).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Best-corrected Distance Visual Acuity (BCDVA) at Final Visit</measure>
    <time_frame>Final Visit (scheduled within window: days 120-180)</time_frame>
    <description>Best-corrected distance visual acuity (BCDVA) at Final Visit, expressed as logarithm of the minimum angle of resolution (logMAR). Corrected means spectacle corrected. Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters were recorded. A decrease in the number of correct letters indicates a decrease in visual acuity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Reduction in Cylinder Within 0.50 Diopter (D) and Within 1.00 D of Intended.</measure>
    <time_frame>Final Visit (scheduled within window: days 120-180)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Uncorrected Distance Visual Acuity (UCDVA) at Final Visit</measure>
    <time_frame>Final Visit (scheduled within window: days 120-180)</time_frame>
    <description>Uncorrected distance visual acuity (UCDVA), expressed as logarithm of the minimum angle of resolution (logMAR). Uncorrected means not spectacle-corrected. Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters were recorded. A decrease in the number of correct letters indicates a decrease in visual acuity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>enVista速 One-Piece Hydrophobic Acrylic Toric IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enVista control lens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spherical control lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>enVista速 One-Piece Hydrophobic Acrylic Toric IOL</intervention_name>
    <description>Test lens having a toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D</description>
    <arm_group_label>enVista速 One-Piece Hydrophobic Acrylic Toric IOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>enVista control lens</intervention_name>
    <description>Spherical Control lens</description>
    <arm_group_label>enVista control lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have a clinically significant cataract in the study eye that is&#xD;
             considered amenable to treatment with standard phacoemulsification cataract&#xD;
             extraction.&#xD;
&#xD;
          -  Subjects must require a lens power from 16.0 D to 27.0 D in the study eye.&#xD;
&#xD;
          -  Subjects must be willing to discontinue contact lens wear for the duration of the&#xD;
             study and, demonstrate stability prior to biometry and surgery in the study eye.&#xD;
&#xD;
          -  Subjects must have a best corrected distance visual acuity (BCDVA) projected to be&#xD;
             better than 20/30 after toric IOL implantation in the study eye.&#xD;
&#xD;
          -  Subjects must have predicted postoperative corneal astigmatism between 0.90D and 2.40D&#xD;
             in the study eye, as determined by the Toric Calculator.&#xD;
&#xD;
          -  Subjects must have a minimum preoperative corneal astigmatism of 0.90 D in the study&#xD;
             eye.&#xD;
&#xD;
          -  Subjects must have a dilated preoperative pupil size greater than or equal to 5.0 mm&#xD;
             in the study eye.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have had previous intraocular or corneal surgery in the study eye.&#xD;
&#xD;
          -  Subjects with any clinically significant ocular pathology which would be expected to&#xD;
             reduce potential BCDVA to 20/30 or worse in the study eye during the course of the&#xD;
             study.&#xD;
&#xD;
          -  Subjects with any anterior segment pathology in the study eye likely to increase the&#xD;
             risk of complications from phacoemulsification cataract surgery.&#xD;
&#xD;
          -  Subjects with associated ocular conditions which could affect the stability of the IOL&#xD;
             in the study eye.&#xD;
&#xD;
          -  Subjects with a traumatic cataract in the study eye.&#xD;
&#xD;
          -  Subjects with uncontrolled glaucoma in the study eye.&#xD;
&#xD;
          -  Subjects with clinically significant irregular corneal astigmatism in the study eye,&#xD;
             as determined by the medical judgment of the Investigator.&#xD;
&#xD;
          -  Subjects with clinically significant corneal pathology potentially affecting&#xD;
             topography of either eye.&#xD;
&#xD;
          -  Subjects with any ocular condition that could prevent the possibility of a visual&#xD;
             outcome better than 20/30 in the study eye.&#xD;
&#xD;
          -  Subjects with a difference of greater than 0.50D of corneal astigmatism as measured&#xD;
             with the IOL Master and the topographer in the study eye using vector analysis.&#xD;
&#xD;
          -  Subjects with an anterior chamber depth &lt;2mm in the study eye.&#xD;
&#xD;
          -  Subjects with potential BCDVA of 20/200 or worse in the fellow eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Packer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 9, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2013</study_first_posted>
  <results_first_submitted>August 11, 2020</results_first_submitted>
  <results_first_submitted_qc>August 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <disposition_first_submitted>December 18, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>November 12, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 16, 2020</disposition_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control IOL</title>
          <description>Control IOL - Spherical control lens</description>
        </group>
        <group group_id="P2">
          <title>Toric IOL1.25 D</title>
          <description>Toric IOL1.25 D - Toric cylinder power of 1.25 diopters (D)</description>
        </group>
        <group group_id="P3">
          <title>Toric IOL 2.00 D</title>
          <description>Toric IOL 2.00 D - - Toric cylinder power of 2.00 diopters (D)</description>
        </group>
        <group group_id="P4">
          <title>Toric IOL 2.75 D</title>
          <description>Toric IOL 2.75 D - Toric cylinder power of 2.75 diopters (D)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control IOL</title>
          <description>Control IOL - Spherical control lens</description>
        </group>
        <group group_id="B2">
          <title>Toric IOL1.25 D</title>
          <description>Toric IOL1.25 D - Toric cylinder power of 1.25 diopters (D)</description>
        </group>
        <group group_id="B3">
          <title>Toric IOL 2.00 D</title>
          <description>Toric IOL 2.00 D - - Toric cylinder power of 2.00 diopters (D)</description>
        </group>
        <group group_id="B4">
          <title>Toric IOL 2.75 D</title>
          <description>Toric IOL 2.75 D - Toric cylinder power of 2.75 diopters (D)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="191"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.5" spread="8.6"/>
                    <measurement group_id="B2" value="71.1" spread="8.8"/>
                    <measurement group_id="B3" value="68.7" spread="9.1"/>
                    <measurement group_id="B4" value="69.6" spread="8.8"/>
                    <measurement group_id="B5" value="70.1" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Dioptric Change in Cylinder</title>
        <description>Dioptric change in cylinder from the preoperative keratometric cylinder magnitude to postoperative manifest refraction cylinder magnitude (referenced to the corneal plane).</description>
        <time_frame>Baseline, Final Visit (scheduled within window: days 120-180)</time_frame>
        <population>Evaluable participants at the specified timepoint are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control IOL</title>
            <description>Control IOL - Spherical control lens</description>
          </group>
          <group group_id="O2">
            <title>Toric IOL1.25 D</title>
            <description>Toric IOL1.25 D - Toric cylinder power of 1.25 diopters (D)</description>
          </group>
          <group group_id="O3">
            <title>Toric IOL 2.00 D</title>
            <description>Toric IOL 2.00 D - - Toric cylinder power of 2.00 diopters (D)</description>
          </group>
          <group group_id="O4">
            <title>Toric IOL 2.75 D</title>
            <description>Toric IOL 2.75 D - Toric cylinder power of 2.75 diopters (D)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Dioptric Change in Cylinder</title>
          <description>Dioptric change in cylinder from the preoperative keratometric cylinder magnitude to postoperative manifest refraction cylinder magnitude (referenced to the corneal plane).</description>
          <population>Evaluable participants at the specified timepoint are included in the analysis.</population>
          <units>diopter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.479" spread="0.665"/>
                    <measurement group_id="O2" value="-0.865" spread="0.487"/>
                    <measurement group_id="O3" value="-1.413" spread="0.532"/>
                    <measurement group_id="O4" value="-1.944" spread="0.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Intraocular Lens (IOL) Rotation of Less Than or Equal to Five Degrees</title>
        <description>Intraocular Lens (IOL) rotation of less than or equal to five degrees between Forms 3 (scheduled within window: days 30-60) and final visit (scheduled within window: days 120-180).</description>
        <time_frame>Form 3 Visit (window: days 30-60), Final Visit (window: days 120-180)</time_frame>
        <population>The measure was not assessed for the control IOL. Evaluable participants at the specified timepoint are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control IOL</title>
            <description>Control IOL - Spherical control lens</description>
          </group>
          <group group_id="O2">
            <title>Toric IOL1.25 D</title>
            <description>Toric IOL1.25 D - Toric cylinder power of 1.25 diopters (D)</description>
          </group>
          <group group_id="O3">
            <title>Toric IOL 2.00 D</title>
            <description>Toric IOL 2.00 D - - Toric cylinder power of 2.00 diopters (D)</description>
          </group>
          <group group_id="O4">
            <title>Toric IOL 2.75 D</title>
            <description>Toric IOL 2.75 D - Toric cylinder power of 2.75 diopters (D)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Intraocular Lens (IOL) Rotation of Less Than or Equal to Five Degrees</title>
          <description>Intraocular Lens (IOL) rotation of less than or equal to five degrees between Forms 3 (scheduled within window: days 30-60) and final visit (scheduled within window: days 120-180).</description>
          <population>The measure was not assessed for the control IOL. Evaluable participants at the specified timepoint are included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Best-corrected Distance Visual Acuity (BCDVA) at Final Visit</title>
        <description>Best-corrected distance visual acuity (BCDVA) at Final Visit, expressed as logarithm of the minimum angle of resolution (logMAR). Corrected means spectacle corrected. Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters were recorded. A decrease in the number of correct letters indicates a decrease in visual acuity.</description>
        <time_frame>Final Visit (scheduled within window: days 120-180)</time_frame>
        <population>Evaluable participants at the specified timepoint are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control IOL</title>
            <description>Control IOL - Spherical control lens</description>
          </group>
          <group group_id="O2">
            <title>Toric IOL1.25 D</title>
            <description>Toric IOL1.25 D - Toric cylinder power of 1.25 diopters (D)</description>
          </group>
          <group group_id="O3">
            <title>Toric IOL 2.00 D</title>
            <description>Toric IOL 2.00 D - - Toric cylinder power of 2.00 diopters (D)</description>
          </group>
          <group group_id="O4">
            <title>Toric IOL 2.75 D</title>
            <description>Toric IOL 2.75 D - Toric cylinder power of 2.75 diopters (D)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Best-corrected Distance Visual Acuity (BCDVA) at Final Visit</title>
          <description>Best-corrected distance visual acuity (BCDVA) at Final Visit, expressed as logarithm of the minimum angle of resolution (logMAR). Corrected means spectacle corrected. Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters were recorded. A decrease in the number of correct letters indicates a decrease in visual acuity.</description>
          <population>Evaluable participants at the specified timepoint are included in the analysis.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.09"/>
                    <measurement group_id="O2" value="0.00" spread="0.09"/>
                    <measurement group_id="O3" value="0.05" spread="0.10"/>
                    <measurement group_id="O4" value="-0.01" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Reduction in Cylinder Within 0.50 Diopter (D) and Within 1.00 D of Intended.</title>
        <time_frame>Final Visit (scheduled within window: days 120-180)</time_frame>
        <population>Evaluable participants at the specified timepoint are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control IOL</title>
            <description>Control IOL - Spherical control lens</description>
          </group>
          <group group_id="O2">
            <title>Toric IOL1.25 D</title>
            <description>Toric IOL1.25 D - Toric cylinder power of 1.25 diopters (D)</description>
          </group>
          <group group_id="O3">
            <title>Toric IOL 2.00 D</title>
            <description>Toric IOL 2.00 D - - Toric cylinder power of 2.00 diopters (D)</description>
          </group>
          <group group_id="O4">
            <title>Toric IOL 2.75 D</title>
            <description>Toric IOL 2.75 D - Toric cylinder power of 2.75 diopters (D)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Reduction in Cylinder Within 0.50 Diopter (D) and Within 1.00 D of Intended.</title>
          <population>Evaluable participants at the specified timepoint are included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Within 0.50 D of intended</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 1.00 D of intended</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Uncorrected Distance Visual Acuity (UCDVA) at Final Visit</title>
        <description>Uncorrected distance visual acuity (UCDVA), expressed as logarithm of the minimum angle of resolution (logMAR). Uncorrected means not spectacle-corrected. Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters were recorded. A decrease in the number of correct letters indicates a decrease in visual acuity.</description>
        <time_frame>Final Visit (scheduled within window: days 120-180)</time_frame>
        <population>Evaluable participants at the specified timepoint are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control IOL</title>
            <description>Control IOL - Spherical control lens</description>
          </group>
          <group group_id="O2">
            <title>Toric IOL1.25 D</title>
            <description>Toric IOL1.25 D - Toric cylinder power of 1.25 diopters (D)</description>
          </group>
          <group group_id="O3">
            <title>Toric IOL 2.00 D</title>
            <description>Toric IOL 2.00 D - - Toric cylinder power of 2.00 diopters (D)</description>
          </group>
          <group group_id="O4">
            <title>Toric IOL 2.75 D</title>
            <description>Toric IOL 2.75 D - Toric cylinder power of 2.75 diopters (D)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Uncorrected Distance Visual Acuity (UCDVA) at Final Visit</title>
          <description>Uncorrected distance visual acuity (UCDVA), expressed as logarithm of the minimum angle of resolution (logMAR). Uncorrected means not spectacle-corrected. Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters were recorded. A decrease in the number of correct letters indicates a decrease in visual acuity.</description>
          <population>Evaluable participants at the specified timepoint are included in the analysis.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.16"/>
                    <measurement group_id="O2" value="0.11" spread="0.14"/>
                    <measurement group_id="O3" value="0.12" spread="0.11"/>
                    <measurement group_id="O4" value="0.13" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>180 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control IOL</title>
          <description>Control IOL - Spherical control lens</description>
        </group>
        <group group_id="E2">
          <title>Toric IOL1.25 D</title>
          <description>Toric IOL1.25 D - Toric cylinder power of 1.25 diopters (D)</description>
        </group>
        <group group_id="E3">
          <title>Toric IOL 2.00 D</title>
          <description>Toric IOL 2.00 D - - Toric cylinder power of 2.00 diopters (D)</description>
        </group>
        <group group_id="E4">
          <title>Toric IOL 2.75 D</title>
          <description>Toric IOL 2.75 D - Toric cylinder power of 2.75 diopters (D)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Epiretinal membrane</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>IOL tilt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anterior lens vault</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal edema</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anterior chamber cell</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anterior chamber flare</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Punctate keratosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Trichiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <email>susan.harris@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

